The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


CILEST 250/35 microgram tablets



Janssen-Cilag LtdPA0748/029/001

Main Information

Trade NameCILEST 250/35 microgram tablets
Active SubstancesNorgestimate
Ethinylestradiol
Dosage FormTablet
Licence HolderJanssen-Cilag Ltd
Licence NumberPA0748/029/001

Group Information

ATC CodeG03FB Progestogens and estrogens, sequential preparations
G03FB05 norethisterone and estrogen

Status

License statusWithdrawn
Withdrawn Date09/10/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - HCP

Educational Materials - Patient

« Back